Methods are disclosed of treating or preventing hypotension (e.g., neurogenic orthostatic hypotension or postprandial hypotension) or portal hypertension (e.g., bleeding esophageal varices associated with portal hypertension) or ascites (e.g., ascites associated with liver cirrhosis), by oral administration to affected subjects of compositions comprising a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof.

Methods are disclosed of treating or preventing hypotension (e.g., neurogenic orthostatic hypotension or postprandial hypotension) or portal hypertension (e.g., bleeding esophageal varices associated with portal hypertension) or ascites (e.g., ascites associated with liver cirrhosis), by oral administration to affected subjects of compositions comprising a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof.

The present invention relates to compounds and compositions for use in a method of treating and/or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and/or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.

The present invention relates to compounds and compositions for use in a method of treating and/or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and/or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001## The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001## The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: ##STR00001## The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder. ##STR00001##